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I M M U N O H E M A T O L O G Y
Case report and literature review: transient Inab phenotype and 
an agglutinating anti-IFC in a patient with a gastrointestinal 
problem
Mark H. Yazer, W. John Judd, Robertson D. Davenport, Louann R. Dake, Christine Lomas-Francis, 
Kim Hue-Roye, Vivien Powell, and Marion Reid
BACKGROUND: The Inab phenotype is a rare deficiency 
of all Cromer antigens. These antigens are carried on the 
decay-accelerating factor (DAF, CD55) molecule that is 
attached to the red blood cell (RBC) membrane by a 
glycosylphosphatidylinositol (GPI) anchor. Although 
typically inherited, an acquired and transient form of the 
Inab phenotype also exists. A patient with the triad of 
transient Inab phenotype, a direct-agglutinating anti-IFC, 
and gastrointestinal (GI) abnormalities is reported.
CASE REPORT: An 18-month-old boy with 
gastroesophageal reflux disease requiring a feeding tube, 
milk and soy intolerance, and severe growth retardation, 
as well as vision and hearing deficits from 
cytomegalovirus infection, was identified when 
pretransfusion testing revealed a potent panagglutinin 
(titer > 2000 at 4°C). This antibody did not react with 
Dr(a–) and IFC RBCs, and the autocontrol was negative. 
The patient’s RBCs lacked CD55 by flow cytometric 
techniques but had normal levels of CD59 and antigens 
such as Yta and Emm, carried on GPI-linked proteins, thus 
excluding paroxysmal nocturnal hemoglobinuria. Several 
months after initial detection, the anti-IFC was virtually 
undetectable and his cells reacted weakly with anti-IFC, 
anti-Dra, and anti-CD55. RBCs from the propositus’ 
parents and brother demonstrated normal CD55 and 
CD59 expression.
CONCLUSION: This is the first example of a direct-
agglutinating anti-IFC. The cause of the transient 
depression in CD55 protein (and thus Cromer system 
antigens) and appearance of anti-IFC remains unknown, 
as does the relationship between the patient’s GI system 
abnormalities and these serologic findings.
here are 14 antigens in the Cromer blood group
system, 11 of high incidence and three of low
incidence (Table 1).1-6 All of these antigens are
located on the complement regulating protein
decay-accelerating factor (DAF, CD55), which is tethered
to the red blood cell (RBC) membrane by a glycosylphos-
phatidylinositol (GPI) anchor.7 There are three molecular
backgrounds that give rise to weakened or absent expres-
sion of Cromer antigens. First, somatic mutations in the
X-linked phosphatidylinositol-glycan-complementation
class A (PIG-A) gene result in a biosynthetic defect in GPI
anchor synthesis and hence the absence of all GPI-linked
proteins on the RBC surface.8 The absence or reduction of
these proteins on RBCs occurs in paroxysmal nocturnal
hemoglobinuria (PNH). In its most extreme form, when
the two main regulators of complement, CD55 and mem-
brane inhibitor of reactive lysis (CD59) are completely
lacking on the RBC surface; intravascular hemolysis
occurs and has been associated with thrombosis
(reviewed in Rosse and Nishimura9).
Second, reduced Cromer system antigen expression
occurs in the case of the rare Dr(a–) RBCs.10 The molecular
basis for this phenotype is a single-nucleotide polymor-
T
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phism (SNP) in exon 5 of DAF, 596C>T, which results in
alternative splicing of the DAF mRNA such that the result-
ing major transcript lacks 44 nucleotides.10-12 In addition,
this alternative splicing shifts the reading frame and intro-
duces a premature stop codon; the translated protein
cannot attach to the membrane and is not present on
the membrane of the RBCs.12 A small minority of the DAF
mRNA transcripts, however, contain this SNP but do not
utilize the cryptic splice acceptor site.13 These minor tran-
scripts are translated normally with the result that there is
a reduced copy number of CD55 and weakened expres-
sion of Cromer system antigens on Dr(a–) cells.13
Third, Inab phenotype RBCs, named after the original
Japanese propositus, lack all Cromer system antigens.14
This rare phenotype has been previously reported in nine
people and is typically recognized by the presence of an
alloantibody (anti-IFC) in their serum to a high-incidence
antigen of the Cromer system absent on these cells
(Table 2).14-20 Several SNPs have been identified underly-
ing this phenotype. The original Japanese propositus14 and
another unrelated Japanese individual18 demonstrated a
nonsense 261G>A polymorphism in exon 2 of the DAF
gene rendering the protein unable to be tethered to the
GPI anchor. Two Japanese individuals with the Inab phe-
notype were reported to have a different SNP, 263C>A,
which causes a 26-bp deletion in the DAF mRNA second-
ary to the activation of a cryptic splice site.17,19 Recently,
another Japanese proband with the Inab phenotype and a
novel nonsense SNP (508C>T, Arg136Stop) was identi-
fied.20 The molecular basis for the Inab phenotype in sev-
eral patients of Jewish,15 Italian,16 and African American18
descent has not been elucidated. Curiously, some of the
first patients with the Inab phenotype were noted to have
a variety of gastrointestinal (GI) system abnormalities,
whereas others with the Inab phenotype lacked these
problems (Table 2).
In addition, there are two reports of transient IFC-
negative individuals. One was a previously healthy Kenyan
national with HbS trait, unexplained splenic infarcts, and
transient Inab phenotype.21 The patient had no GI abnor-
malities and had never received a transfusion, yet an anti-
IFC–reactive at indirect antiglobulin test (IAT) was present
in his serum sample, and his cells were clearly lacking
CD55 by flow cytometric analysis.21 More recently, an
elderly female patient with chronic lymphocytic leukemia
and transient Inab phenotype with anti-IFC was
reported.22 We report another example of a patient with
transient Inab phenotype, who unlike
the previous transient Inab phenotype
propositi, had GI abnormalities and a
direct agglutinating anti-IFC.
CASE REPORT
The propositus is a Caucasian male
born at 38 weeks’ gestation with con-
genital cytomegalovirus disease causing
blindness and deafness. The patient had
severe growth retardation (height, first
percentile; weight, 0 percentile) and
suffered significant gastroesophageal
reflux disease as well as milk and soy
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* Adapted from Reid et al., 2 Storry et al.,3 Banks et al.,4 Storry and Reid,5 Ivankovic et al.6
TABLE 2. Comparison of all reported individuals with Inab phenotype
Author Ethnicity Anti-IFC GI abnormalities* Transient SNP
This study Caucasian Yes GERD, food intolerances Yes None
Hue-Roye et al. 20 Japanese Yes None No 508C>T
Banks et al.22 Swedish Yes None Yes Unknown
Uchikawa et al.19 Japanese Yes Unknown No 263C>A
Matthes et al.21 Kenyan Yes None Yes None
Daniels et al.18 Japanese Yes Capillary angioma No 261G>A
African American Yes PLE No Unknown
Wang et al.17 Japanese Unknown None No 263C>A
Lin et al.16 Italian American Yes None No Unknown
Italian American No None No Unknown
Walthers et al.15 American Yes Crohn’s disease No Unknown
Daniels et al.14 Japanese Yes PLE No 261G>A
* GERD = gastroesophageal reflux disease; PLE = protein-losing enteropathy.
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intolerances such that a feeding tube was required. At age
1 year (April 2004), he came to the attention of the blood
bank when routine pretransfusion testing, performed in
advance of cochlear implant surgery, revealed an ABO
typing discrepancy due to a potent panagglutinin. Addi-
tional samples were obtained when the patient returned
for a follow-up visit at age 16 months (August 2004). At
that time his complete blood count was within normal
limits. Additional samples were also obtained after sur-
gery at age 18 months (October 2004).
MATERIALS AND METHODS
RBC serology
Standard serologic techniques were performed through-
out this case study investigation.23 Reagent RBCs and
antibodies to blood group antigens were from either
ImmucorGamma (Norcross, GA) or Ortho Clinical Diag-
nostics (Raritan, NJ), or from the private collections of our
institutions. Gel column technology was from Ortho Clin-
ical Diagnostics.
Immunoglobulin G (IgG) monoclonal antibodies to
CD55 and CD59 were a gift from G. Halverson of the Lind-
say F. Kimball Research Institute at the New York Blood
Center and were tested against RBCs in gel columns con-
taining mouse anti-IgG (MicroTyping Systems, Pompano
Beach, FL). Escherichia coli (E. coli 12F), containing the
075X adhesin (Dra adhesin),24 was a gift from C.F. Marrs
(School of Public Health, University of Michigan). Bacte-
rial hemagglutination tests were performed on buffered
gel cards (Ortho Clinical Diagnostics) as described
previously.25
Flow cytometry
Washed RBCs (50 µL, 3% suspension) were incubated
with IgG monoclonal anti-CD55 and CD59 (50 µL) for
30 minutes at room temperature. After being washed, the
RBCs were incubated with fluorescein isothiocyanate
(FITC)-labeled mouse anti-IgG, washed, and then resus-
pended in 500 µL of phosphate-buffered saline-1 percent
paraformaldehyde. After fixation, cells were analyzed by
one-color flow cytometry (FACScan, Becton Dickinson,
Hialeah, FL) with the accompanying software (Cell-Quest,
Becton Dickinson). Cells were gated on forward and
orthogonal scatter, and the percentage FITC-positive cells
was determined. All samples were stained in duplicate
and recorded as the mean percent positive cells and mean
channel fluorescence.
Sequencing of DNA
Genomic DNA was isolated from whole blood (QIAamp
blood kit, Qiagen, Inc., Valencia, CA). The regions of DAF
that include and flank exon 2, exon 3, exon 4, exon 5, and
exon 6 (which encode SCRs 1-4) were individually ampli-
fied with sets of primers derived from Banks and col-
leagues4 and Telen and coworkers26 with modified primers
DAFSCR2R (GAGTTCTAGCATGAATGAAGGAAGGG) and
DAFSCR4F (GCATCTCTTGTTGGTAATGCTGG). The prim-
ers were synthesized by Life Technologies, Inc. (Gaithers-
burg, MD). Two microliters of DNA per reaction was
amplified by 5 U Taq DNA polymerase (HotStarTaq,
Qiagen) in a 50-µL reaction mixture containing 2.0 mmol
per L MgCl2 (1.5 mmol/L MgCl2 for exon 2 primers), 1×
PCR buffer, 0.2 mmol per L dNTPs, and 100 ng of forward
and reverse primer. Amplification was achieved over 35
cycles with a final extension time of 10 minutes. The PCR
products were sequenced directly in the Laboratory of
Microchemistry at the New York Blood Center with an
automated DNA sequencer (ABI 373XL, Applied Biosys-
tems, Inc., Foster City, CA), and reagents (ABI Big Dye
reagents with BD Half-Term, GenPak, Stony Brook, NY).
The PCR products were sequenced in both directions.
RESULTS
Serology
April through August 2004. The following descrip-
tion combines the serologic findings from the propositus’
April and August 2004 blood samples. Unexpected reactiv-
ity with A1 cells on the serum ABO typing of this apparent
group A patient was noted. Additional studies revealed a
strongly reactive panagglutinin (2-3+S) in immediate-spin
tests with all panel cells tested, including a sample from
cord blood. Much weaker (microscopic 1+ to 1+s) reactiv-
ity was noted with all panel cells tested at albumin 37°C,
at albumin IAT, and by papain IAT. The autologous control
was negative in all phases of testing. The antibody failed
to agglutinate cells when saline was then added in place
of AHG reagent in the IAT.
The maximum titer of this panagglutinin was 2000 at
4°C. It agglutinated RBCs of the following rare phenotypes:
Emm–, Gy(a–), MkMk, p, and P2k and did not agglutinate
Dr(a–), IFC–, and type III PNH. The antigen recognized by
this panagglutinin was ficin-, papain-, and trypsin-resis-
tant but α-chymotrypsin-sensitive. The failure of this anti-
body to agglutinate Dr(a–), IFC–, and type III PNH RBCs,
along with its reaction pattern with enzyme-treated RBCs,
was suggestive of an antibody to a high-prevalence anti-
gen of the Cromer blood group system.
The patient’s RBCs were negative in the DAT. The
extended phenotype of his RBCs revealed that he was pos-
itive for the following antigens: A, D, C, E, c, e, M, S, s, Fya,
Fyb, Jka, Jkb, Wrb, Yta, I, P, Vel, and Emm. His RBCs were
negative for the following antigens: N, P1, K, Dra, and IFC.
His RBCs did not react with anti-CD55 when tested on
mouse anti-IgG gel cards nor did they demonstrate agglu-
tination in gel cards containing E. coli 12F with the 075X
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adhesin.25 Overall, in view of the IFC-negative phenotype
of the propositus, this antibody is considered to have anti-
IFC specificity, although typically anti-IFC would be
expected to react weakly with Dr(a–) RBCs.
October 2004. The antibody detecting a high-preva-
lence antigen of the Cromer blood group system was vir-
tually undetectable in his serum sample; it reacted only
microscopically by albumin IAT with one of six panel cells
tested and also with a cord RBC sample. The propositus’
plasma also reacted weakly at room temperature with four
of seven RBC samples suspended in saline. As before, the
patient’s RBCs were negative in the DAT, but his RBC phe-
notype had changed such that his cells were now weakly
reactive with anti-Dra and anti-IFC. His RBCs still failed to
be agglutinated by E. coli 12F. Weak reactivity was now
observed when his cells were tested with monoclonal anti-
CD55 by mouse anti-IgG gel cards. At this time the RBCs
of his mother, father, and brother were also obtained and
evaluated for the expression of CD55;
these family members demonstrated
normal expression of CD55.
Flow cytometry
CD55 was virtually absent from the
RBCs of the propositus in August (gated
events, 1.6 percent of control; Fig. 1).
However, in October the number of
CD55-positive cells (gated events) had
increased to 28 percent of control. CD59
was expressed normally in specimens
from both dates. This finding, taken
together with the presence of the GPI-
anchored Yta and Emm antigens on his
RBCs, excludes PNH as the cause of
reduced CD55 expression. The levels of
CD55 and CD59 were also evaluated on
RBCs from his parents and his brother
in October: as in agglutination-based
studies, RBCs of these family members
demonstrated normal CD55 and CD59
expression.
Sequencing of DNA
Exons 2 through 6 of DAF and their
flanking intronic sequences were
sequenced and found to be identical to
the consensus sequence.
DISCUSSION
This is the first report of a patient with
the triad of GI abnormalities, transient
Inab phenotype, and a direct aggluti-
nating antibody directed at a high-prevalence Cromer
antigen. The specificity is considered to be anti-IFC based
on the findings that the patient’s RBCs were IFC– and that
the antibody did not agglutinate IFC– or Dr(a–) RBCs. The
failure to agglutinate Dr(a–) RBCs is most likely due to the
very low levels of Cromer antigens expressed on RBCs with
this phenotype. Unlike a previous case report of a patient
with transient Inab phenotype with anti-IFC,21 our patient
did not manifest thrombotic complications, although in
both cases a generalized absence of GPI-linked proteins
was excluded by the presence of normal amounts of CD59
on the RBC surface. Exons 2 through 6 of DAF were con-
sensus in both propositi. Unfortunately, we have been
unable to obtain further blood samples from the current
propositus and his family, nor can we be certain of the
length of time the current propositus had the transient
Inab phenotype with the anti-IFC. It is interesting to note
that the anti-IFC reported here was a direct agglutinin that
Fig. 1. Comparison of the expression of CD55 on the propositus’ RBCs in August 2004 
(A) and again in October 2004 (B). In August, most of his cells (98.4%) had a complete 
absence of CD55. In October a significant proportion of his RBCs demonstrated 
increasing levels of CD55, and his circulating anti-IFC was virtually undetectable. (C) 
Positive control (RBCs donated by a healthy laboratory volunteer); (D) isotype 
control.
A















































































TRANSIENT INAB AND AGGLUTINATING ANTI-IFC
Volume 46, September 2006 TRANSFUSION 1541
reacted strongly at 4°C but there was also reactivity, albeit
weaker, at IAT; however, reactivity was absent when saline
was added in place of the AHG reagent. There is precedent
for changes in the GI flora stimulating transient anti-
blood group antibodies: a 20-day old, K– neonate with
sepsis caused by the uncommon E. coli variant O125:B15
produced anti-A and anti-K. Both antibodies were IgM
and not of maternal origin. Cell-free isolates of these bac-
teria could inhibit the agglutination caused by these anti-
bodies and thus bacteria were presumed to have been the
sensitizing stimulus. When the infection resolved, the
antibodies disappeared.27
Still, the stimulus for developing the current anti-IFC,
as in the two previous reports of patients with transient
Inab with anti-IFC remains unclear.21,22 The patient in the
earlier report had been a blood donor for many years
before developing this antibody, and no unexpected anti-
bodies had been detected in his serum at the time of his
donations.21 The other patient with transient Inab pheno-
type had not been previously transfused, but had been
pregnant (J. Poole, personal communication, June 2005).22
The current propositus was a very young male who had
also never been transfused. Although we do not have a
blood sample from before April 2004, the appearance and
subsequent disappearance of the anti-IFC most likely cor-
relates to the presence (and absence) of the corresponding
antigen on the patient’s RBCs. Anti-IFC is not invariably
present in people with the Inab phenotype: a 70-year-old
Italian-American individual who, along with his sister,
inherited the Inab phenotype did not demonstrate anti-
IFC; given that both he and his sister demonstrated this
rare phenotype, it is most likely inherited. Thus anti-IFC
is not necessarily present in Inab individuals, even those
with a genetic etiology to their phenotype.16 The appear-
ance of anti-IFC was also noted in the original Inab prop-
ositus who presented with an anti-IFC; he had received
transfusion of fresh-frozen plasma but apparently not
RBCs.14
A common thread linking the first few reports of
patients with the Inab phenotype was that these propositi
had GI system abnormalities; the original propositus
(Inab) had a protein-losing enteropathy,14 as did a 12-year-
old African American boy who almost certainly had the
Inab phenotype.18 Walthers and coworkers15 reported a
third Inab phenotype patient who had Crohn’s disease,
whereas Daniels reported a Japanese woman with the
Inab phenotype who suffered from blood capillary angi-
oma of the small intestine.18 Although CD55 is known to
be expressed on numerous epithelial surfaces including
the gut,28 a causal association between its deficiency and
anatomical lesions of the gut has not been established.
DAF knock-out mice had heightened susceptibility to dex-
tran sulfate sodium–induced colitis, suggesting its role in
protecting the gut from insult.29 These similarities have to
be interpreted in light of the six other Inab phenotype
patients, including the two transient Inab patients,21,22
who did not demonstrate nor have a history of GI
abnormalities.16,17,20
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